Short Interest in Invesco Biotechnology & Genome ETF (NYSEARCA:PBE) Increases By 27.9%

Invesco Biotechnology & Genome ETF (NYSEARCA:PBE) saw a significant increase in short interest during the month of January. As of January 30th, there was short interest totaling 3,281 shares, an increase of 27.9% from the January 15th total of 2,565 shares. Based on an average daily trading volume, of 10,160 shares, the short-interest ratio is currently 0.3 days. Approximately 0.1% of the shares of the stock are short sold. Approximately 0.1% of the shares of the stock are short sold. Based on an average daily trading volume, of 10,160 shares, the short-interest ratio is currently 0.3 days.

Invesco Biotechnology & Genome ETF Trading Up 0.9%

PBE traded up $0.73 during trading hours on Tuesday, hitting $82.28. The company’s stock had a trading volume of 3,251 shares, compared to its average volume of 7,169. The business’s 50-day moving average price is $82.32 and its 200-day moving average price is $75.99. Invesco Biotechnology & Genome ETF has a 12 month low of $54.52 and a 12 month high of $85.73. The stock has a market cap of $264.10 million, a price-to-earnings ratio of 20.44 and a beta of 0.79.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of PBE. Gerber Kawasaki Wealth & Investment Management boosted its holdings in shares of Invesco Biotechnology & Genome ETF by 4.2% in the 2nd quarter. Gerber Kawasaki Wealth & Investment Management now owns 254,172 shares of the company’s stock valued at $16,292,000 after buying an additional 10,213 shares in the last quarter. RFG Advisory LLC purchased a new stake in Invesco Biotechnology & Genome ETF during the second quarter valued at approximately $300,000. Allworth Financial LP purchased a new stake in shares of Invesco Biotechnology & Genome ETF during the 2nd quarter valued at $54,000. Stratos Wealth Partners LTD. purchased a new stake in shares of Invesco Biotechnology & Genome ETF during the 4th quarter valued at $260,000. Finally, Q3 Asset Management acquired a new stake in shares of Invesco Biotechnology & Genome ETF in the 4th quarter worth $1,431,000.

About Invesco Biotechnology & Genome ETF

PowerShares Dynamic Biotechnology & Genome Portfolio (the Fund) is based on the Dynamic Biotechnology & Genome Intellidex Index (the Index). The Fund seeks investment results that correspond generally to the price and yield of the Index. The Index consists of stocks of 30 the United States biotechnology and genome companies. The Fund will normally invest at least 90% of its total assets in common stocks that consists of the Index. The Index is designed to provide capital appreciation by evaluating companies based on a variety of investment merit criteria, including fundamental growth, stock valuation, investment timeliness and risk factors.